Harry Finch

Harry has significant experience within the pharmaceutical industry, specialising in medicinal chemistry, drug discovery and development. More recently he acted as an independent consultant working with a variety of small biotech companies and investors, many of which are in the oncology arena. Harry has had non-executive director roles in, C4X Discovery, Pulmocide Therapeutics and Artios Pharma Ltd. Prior to attaining a PhD in Organic Chemistry, Harry worked at Ciba-Geigy AG (now Novartis AG) but subsequently joined Roche followed by Allen & Hanburys / Glaxo Limited. At GlaxoWellcome plc he became Director of Chemistry. Harry has considerable experience in the respiratory area and is co-inventor of GSK’s successful asthma drug salmeterol (Serevent). In addition, he has worked across a range of therapeutic areas and at several biotechnology companies, including Ribotargets, Vernalis, Argenta Discovery and Pulmagen Therapeutics. Harry founded Kesmalea Therapeutics in 2020.